Cadrenal Therapeutics CFO Disposes of 2,000 Shares in Open-Market Sales

Rhea-AI Filing Summary

Cadrenal Therapeutics insider transaction: The company's Chief Financial Officer, Matthew K. Szot, reported two open-market sales of common stock. He sold 1,600 shares on 08/27/2025 at a weighted-average price of $13.995 and sold 400 shares on 08/28/2025 at $14.00. After the first sale he reported beneficial ownership of 31,733 shares and after the second sale 31,333 shares. The Form 4 indicates these were non-derivative dispositions and includes footnotes that the reported prices reflect multiple trades within the stated ranges.

Positive

• Timely disclosure of insider sales via Form 4, including explanatory footnotes on weighted-average prices

Negative

• Officer stock sales totaling 2,000 shares, which may be viewed negatively by some investors though size appears modest

Insights

Securities Analyst

TL;DR: Officer sold a modest number of shares in two transactions; disclosure is routine and non-material relative to total float.

The CFO executed two small open-market sales totaling 2,000 shares at roughly $14 per share. The filing shows routine Section 16 reporting and price footnotes indicating multiple trades. There is no derivative activity reported and the remaining beneficial ownership after the transactions is 31,333 shares. From a market-impact perspective, these transactions appear modest and the Form 4 provides standard transparency.

Corporate Governance Expert

TL;DR: Disclosure meets Rule 16 reporting expectations; sales are documented with price-range footnotes.

The report identifies the reporting person as the CFO and confirms timely disclosure of two non-derivative sales. The explanatory footnotes clarify that reported prices are weighted averages from multiple trades, which supports record accuracy. No exemptions or plans (e.g., Rule 10b5-1) are explicitly referenced as the basis for the trades on the form, beyond an initial checkbox; the filing itself remains a straightforward compliance disclosure rather than a governance event.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Szot Matthew K

(Last) (First) (Middle)

C/O CADRENAL THERAPEUTICS, INC.,

822 A1A NORTH, SUITE 306

(Street)

PONTE VEDRA FL 32082

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cadrenal Therapeutics, Inc. [ CVKD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/27/2025		S		1,600	D	$13.995(1)	31,733	D
Common Stock	08/28/2025		S		400	D	$14(2)	31,333	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 through $14.00. The reporting person undertakes to provide to Cadrenal Therapeutics, Inc., any security holder of Cadrenal Therapeutics, Inc. or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions, each at $14.000. The reporting person undertakes to provide to Cadrenal Therapeutics, Inc., any security holder of Cadrenal Therapeutics, Inc. or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Matthew K. Szot	08/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions were reported for Cadrenal Therapeutics (CVKD)?

The Chief Financial Officer sold 1,600 shares on 08/27/2025 at a weighted-average $13.995 and 400 shares on 08/28/2025 at $14.00.

How many shares did the reporting person own after the transactions?

The filing shows 31,733 shares after the 08/27 sale and 31,333 shares after the 08/28 sale.

Were these sales of common stock or derivative transactions?

These were non-derivative common stock dispositions, not option exercises or other derivative transactions.

Do the reported prices reflect single trades or multiple trades?

Footnotes state the prices are weighted averages reflecting multiple transactions within the $13.99–$14.00 range.

Is there an indication these trades were part of a Rule 10b5-1 plan?

The filing includes a checked box indicating a transaction pursuant to a written plan may apply, but the Form 4 does not provide further plan details.